Development of injection for osteoarthritis knee pain fast tracked in the US

Share Button

knee pain, knee arthritis, knee osteoarthritis, new arthritis drug, new arthritis treatmentA synthetic injection of trans-capsaicin for the treatment of pain linked with knee osteoarthritis has been given the green light for quick development in the US.

CNTX-4975 is injected directly at the site of joint pain to provide rapid and long-lasting pain relief for people with moderate-to-severe osteoarthritis knee pain.

People with osteoarthritis knee pain for whom previous pain relief hadn’t worked, found significant pain relief continuing beyond 24 weeks from a single 1mg injection of CNTX-4975. And they enjoyed improved knee stiffness and physical function during the trial. CNTX-4975 was well-tolerated too, having a safety profile similar to placebo.

“We look forward to building on the momentum of our CNTX-4975 program with the initiation of our phase 3 program in patients with moderate-to-severe knee osteoarthritis in the first quarter of 2018,” says Dr Randall Stevens from Centrexion Therapeutics, the company behind the drug.

Click here for the latest osteoarthritis news stories.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.

“Amazing magazine and the first I’ve read from beginning to end.” Mrs E Crowther, Dorset

“There’s so much news and information to digest, and it’s all calorie free. Brilliant!” A Alexander, Glasgow
“As we are all living longer, it gives us hope for a future with less pain. Arthritis Digest gives us information on the up to date treatments.”Mrs Healey, Devon
“Full of interesting information and tips.” Mr G Thurlow, East Yorkshire

Google+ | Privacy Policy | FTC Disclaimer

Copyright © 2013. All Rights Reserved.